Drug Trials Snapshots: TEVIMBRA (tislelizumab-jsgr)

TEVIMBRA is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of adults with a type of esophageal cancer called esophageal squamous cell carcinoma (ESCC) that has spread to other parts of the body (metastatic) or cannot be completely removed by surgery (unresectable). It is approved to treat patients who have undergone prior treatment with chemotherapy for their ESCC that did not include a PD-1 blocking antibody. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tevimbra